Targeting mesothelin in cancer
Mol Ther Oncolytics
.
2023 Dec 3:31:100756.
doi: 10.1016/j.omto.2023.100756.
eCollection 2023 Dec 19.
Author
Cem Elbi
1
Affiliation
1
Oncology Development Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
PMID:
38075245
PMCID:
PMC10701581
DOI:
10.1016/j.omto.2023.100756
No abstract available
Publication types
News